The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Parnassus Investments, an investment management company, released the "Parnassus Growth Equity Fund" second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index's 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services and Financials holdings detracted. For the year-to-date period, the Fund returned 6.17% (net of fees), outperforming the Russell 1000 Growth's 5.33%. The firm remains constructively bullish on U.S. equities and continues to be selective, valuation-sensitive, and focused on disruptive growth opportunities through active stock selection. Growth stocks advanced during the second quarter, as the Russell 1000 Growth Index generated strong double-digit returns driven by increased confidence in the durability of the ongoing artificial intelligence (AI) infrastructure build-out. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its second-quarter 2026 investor letter, Parnassus Growth Equity Fund highlighted Medline Inc. (NASDAQ:MDLN). Medline Inc. (NASDAQ:MDLN) manufactures med-surg products serving hospitals, surgery centers, physician offices, post-acute facilities, and nursing home sites of care. On September 15, 2026, Medline Inc. (NASDAQ:MDLN) closed at $36.59 per share. Over the past month, Medline Inc. (NASDAQ:MDLN) declined 4.23%, and YTD its shares lost 22.68%. Medline Inc. has a market capitalization of $42.22 billion.
Parnassus Growth Equity Fund stated the following regarding Medline Inc. (NASDAQ:MDLN) in its Q2 2026 investor letter:
"Medline Inc. (NASDAQ:MDLN) shares declined as medical technology stocks broadly came under pressure. The company also faced near term concerns surrounding tariffs and higher transportation costs, though we remain confident in its long-term competitive positioning."
Medline Inc. (NASDAQ:MDLN) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 52 hedge fund portfolios held Medline Inc. (NASDAQ:MDLN) at the end of the second quarter which was 65 in the previous quarter. While we acknowledge the potential of Medline Inc. (NASDAQ:MDLN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
In another article, we discussed Medline Inc. (NASDAQ:MDLN) and shared Artisan Global Opportunities Strategy's views on the company. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
This article is originally published at Insider Monkey.
Artisan Sold Medline (MDLN) as Cost Pressures Delayed the Company’s Profit Recovery Insider Monkey • 12d ago MDLN
Artisan Sold Medline (MDLN) as Cost Pressures Delayed the Company’s Profit Recovery
Brown Advisory Mid-Cap Growth Strategy Bets on Medline (MDLN) in IPO Insider Monkey • 5mo ago MDLN PLTR
Brown Advisory Mid-Cap Growth Strategy Bets on Medline (MDLN) in IPO
Is Medline Inc. (MDLN) A Good Stock To Buy Now? Insider Monkey • 5mo ago MDLN MCK
Is Medline Inc. (MDLN) A Good Stock To Buy Now?
Is Medline (MDLN) One of the Best Healthcare Stocks to Buy With the Highest Upside Potential? Insider Monkey • 3mo ago MDLN
Is Medline (MDLN) One of the Best Healthcare Stocks to Buy With the Highest Upside Potential?
Medline Inc. (MDLN) Shares Up Since Jim Cramer Said It Could Be A Buy Insider Monkey • 2mo ago MDLN
Medline Inc. (MDLN) Shares Up Since Jim Cramer Said It Could Be A Buy
Is Medline (MDLN) One of the Best Up and Coming Stocks to Invest In Right Now? Insider Monkey • 2mo ago MDLN
Is Medline (MDLN) One of the Best Up and Coming Stocks to Invest In Right Now?
Medline Inc (MDLN) Plans to Expand Distribution Centers Insider Monkey • 5mo ago MDLN
Medline Inc (MDLN) Plans to Expand Distribution Centers
Medline (MDLN) Signs New Prime Vendor Agreement With CarDon Insider Monkey • 5mo ago MDLN
Medline (MDLN) Signs New Prime Vendor Agreement With CarDon
Revolution Medicines’ (RVMD) Promising Clinical Results Signal Potential Paradigm Shift Insider Monkey • 47m ago RVMD
Revolution Medicines’ (RVMD) Promising Clinical Results Signal Potential Paradigm Shift
Assessing Medline (MDLN) Valuation After Recent Share Price Pullback Simply Wall St. • 3mo ago MDLN
Assessing Medline (MDLN) Valuation After Recent Share Price Pullback
